DUBLIN, January 8, 2013 /PRNewswire/ --
- Shire plc (LSE: SHP, NASDAQ: SHPG)
Angus Russell, Chief Executive
Officer of Shire, will address investors today at the JP Morgan
Healthcare Conference in San
Francisco. In his address he will confirm that Shire
expects to deliver double digit full year earnings growth for 2012,
and looking ahead, Shire is now increasingly confident of meeting
current consensus earnings expectations(1)for 2013.
Angus' presentation will be webcast live today, at 11:00 AM PST/2:00 PM
EST/7:00 PM GMT
Investors can access the live webcast here
http://jpmorgan.metameetings.com/webcasts/healthcare13/directlink?ticker=SHP.L
(1) Based on the most recent consensus estimates compiled
by Consensus Forecast Ltd, as of the date of this press release, of
$6.69 Non GAAP diluted earnings per
ADS for the year ended 31 December
2013, included on Shire's website
(http://www.shire.com/shireplc/en/investors/forecasts).
Notes to editors
Shire enables people with
life-altering conditions to lead better lives.
Through our deep understanding of patients' needs, we develop
and provide healthcare in the areas of:
- Behavioral Health and Gastro Intestinal conditions
- Rare Diseases
- Regenerative Medicine
as well as other symptomatic conditions treated by specialist
physicians.
We aspire to imagine and lead the future of healthcare, creating
value for patients, physicians, policymakers, payors and our
shareholders.
"SAFE HARBOR" STATEMENT UNDER THE
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are
forward-looking statements. Such forward-looking statements involve
a number of risks and uncertainties and are subject to change at
any time. In the event such risks or uncertainties materialize, the
Company's results could be materially adversely affected. The risks
and uncertainties include, but are not limited to, risks associated
with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the Company's
Specialty Pharmaceuticals, Human Genetic Therapies and Regenerative
Medicine products, as well as the ability to secure new products
for commercialization and/or development; government regulation of
the Company's products; the Company's ability to manufacture its
products in sufficient quantities to meet demand; the impact of
competitive therapies on the Company's products; the Company's
ability to register, maintain and enforce patents and other
intellectual property rights relating to its products; the
Company's ability to obtain and maintain government and other
third-party reimbursement for its products; and other risks and
uncertainties detailed from time to time in the Company's filings
with the Securities and Exchange Commission.
For further information please contact:
Investor Relations
Eric Rojas
erojas@shire.com
+1-781-482-0999
Sarah Elton-Farr
seltonfarr@shire.com
+44-1256-894157
Media
Jessica Mann
jmann@shire.com
+44-1256-894-280
Gwen Fisher
gfisher@shire.com
+1-484-595-9836
